Search for a trial

PRESERVE TRIAL:
Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects. A 52-week randomized controlled factorial study in subjects with IFG and/or IGT.

Amendment 2007: PancREatic beta-cell dySfunction rEstoRed by Valsartan Effects – PRESERVE Study.

Amendment 2007: In stead of two medicaments (Rosiglitazon and valsartan), only valsartan has been completed. Due to negative publicity, Rosiglitazon was stopped. Target number of participant is thereby decreased from 144

Type 2 diabetes is cause by progressive beta-cell dysfunction against a background of obesity and insulin resistance in susceptible individuals. Peroxisome proliferator-activated receptor (PPAR) gamma-mediated mechanisms are involved in the…

Prevention of Osteoarthritis in Overweight Females.

The present study is a feasibility study. In this study we will test the feasibility of the procedures used, the compliance to the interventions, and the usefulness of intermediate outcome measures in a specific high risk group. If the results of…